Evidence map›Paper›PMID 39386887›Full record

ArticleAlcoholism treatment quarterly2024

A Pilot Study: Treatment of High Alcohol Consumption in a Novel Minipig Model of Alcohol Use Disorder.

Xiaobo Liu, Praneetha Panthagani, Ana G Gutierrez, Arlette Vega, Abdul A Shaik, Monica G Aguilera, Jordan N Sanchez, Joshua O Willms, Brittany Backus, Bruce Blough and 5 more

Abstract read
In one paragraph

Article in Alcoholism treatment quarterly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiaobo LiuDepartment of Pharmacology & Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.ORCID 0000-0002-2492-4537
Praneetha PanthaganiDepartment of Pharmacology & Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Ana G GutierrezDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Arlette VegaDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Abdul A ShaikDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Monica G AguileraDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Jordan N SanchezDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Joshua O WillmsDepartment of Pharmacology & Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Brittany BackusDepartment of Animal and Food Sciences, Texas Tech University, Lubbock, Texas, USA.
Bruce BloughRTI International, Research Triangle Park, North Carolina, USA.
Elliott PauliRTI International, Research Triangle Park, North Carolina, USA.
Ted W ReidDepartment of Ophthalmology & Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Thomas BentonRTI International, Research Triangle Park, North Carolina, USA.
Jeremy D BailooDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.ORCID 0000-0002-3767-2922
Susan E BergesonDepartment of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.ORCID 0000-0002-4657-8954

Funding

Supplement to: Medication Development for the Treatment of Alcohol Use Disorder - U01AA028957U01AA028957 · NIAAA · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI BERGESON, SUSAN E., SHEN, CHWAN-LI L · 2020 to 2025
$7.8M
Chemically modified minocycline for treatment of alcohol use disorderU01AA027401 · NIAAA · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI BACKUS, BRITTANY LEILANI, BERGESON, SUSAN E. · 2018 to 2019
$1.6M
NIAAA NIH HHS U01 AA027401NIAAA NIH HHS U01 AA028957
6 · The paper itself

Abstract

Three medications are FDA approved in the US for treatment of Alcohol Use Disorder (AUD), and a few others are used off-label. Patient compliance and efficacy in the broader population are major hurdles for current AUD medications. As a consequence, there is an urgent need for improved pharmacotherapeutics to complement behavioral approaches. Here, we report pilot testing of a minocycline analog, 10-butylether minocycline (BEM, 10 mg/kg p.o.), in two female minipigs with free-choice drinking to intoxication for nearly two and a half years. Each pig met DSM-5 criteria for diagnosis of severe AUD, and BEM reduced both alcohol intake and preference. BEM is currently undergoing testing for approval as an Investigational New Drug by the FDA for AUD treatment.

Indexed as

Alcohol use disordermedication developmentpharmacotherapeuticspre-clinicaltreatment

Identifiers

PMID39386887
PMCPMC11463722

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.